LLY Eli Lilly and Company Common Stock
$1287,96
Prezzo · Ago 19, 2026
Fondamentali al Ago 5, 2026
Intervallo 52 sett.
$685–$1293
99% of range
Rating Analisti
BUY
38 analysts
Prezzo Obiettivo
$1299
+1% upside
P/E (TTM)
46.8
ROE
101.2%
Margine di Profitto Netto
31.7%
Informazioni su Eli Lilly and Company Common Stock Panoramica della società da Wikipedia
Eli Lilly and Company è un'azienda farmaceutica statunitense con sede a Indianapolis. I suoi prodotti sono venduti in circa 125 paesi e l'azienda ha propri uffici in 18 di essi.
Leggi di più
Eli Lilly and Company è un'azienda farmaceutica statunitense con sede a Indianapolis. I suoi prodotti sono venduti in circa 125 paesi e l'azienda ha propri uffici in 18 di essi.
Storia
La compagnia fu fondata nel 1876 dal colonnello Eli Lilly, un chimico farmaceutico e veterano della guerra civile americana, da cui prese il nome la compagnia.
La Eli Lilly è stata la prima azienda a produrre in serie il vaccino contro la poliomielite sviluppato da Jonas Salk e l'insulina; inoltre è stata una delle prime aziende farmaceutiche a produrre insulina umana, utilizzando il DNA ricombinante, incluso Humulin (farmaco insulinico), Humalog (insulina lispro) e il primo prodotto insulinico biosimilare approvato negli Stati Uniti, Basaglar (insulina glargine).
A luglio 2016 Dave Ricks è stato nominato CEO della Eli Lilly.
Nel novembre 2025 diventa la prima azienda farmaceutica statunitense a superare i mille miliardi di dollari di capitalizzazione di borsa.
Prodotti
Lilly è il più grande produttore mondiale di farmaci psichiatrici, tra cui Prozac (fluoxetina), Dolophine (metadone), Cymbalta (duloxetina) e Zyprexa (olanzapina). È altresì leader nella produzione, per la terapia del diabete mellito di tipo 1 e 2, dell’analogo dell’insulina da DNA ricombinante Humalog (insulina Lispro) in flacone e in penna (in questo secondo caso, in due concentrazioni u/ml 100 e U/ml 200 iniettabili attraverso la kwikpen). Particolare successo hanno poi avuto il Mounjaro, farmaco per tenere sotto controllo il diabete, e lo Zepbound, indicato nei trattamenti contro l’obesità; entrambi i preparati sono basati sul medesimo principio attivo, che rientra nella classe degli agonisti dei recettori GLP-1.
Ha poi immesso in commercio la dulaglutide (trulicity), un GLP1 a somministrazione settimanale per il controllo della glicemia nel DMT2 in maniera glucosio dipendente.
Fonte: Wikipedia, CC BY-SA 4.0 · Vedi su Wikipedia ↗
LLY Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$1287.95
Capitalizzazione di Mercato
—
P/E (TTM)
46.8
EPS (TTM)
$22.95
Ricavi (TTM)
$65.18B
Rendimento div.
—
ROE
101.2%
D/E Debito/Patrimonio
1.5
Intervallo 52 sett.
$685 – $1293
LLY Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$65.18B
2016-12-31
→
2025-12-31
EPS
$22.95
2016-12-31
→
2025-12-31
Flusso di cassa libero
—
Margini
31.7%
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
LLY
Mediana dei peer
P/E (TTM)
46.8
53.4
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
LLY
Mediana dei peer
Net Profit Margin (Margine di Profitto Netto)
31.7%
-24.7%
ROA
21.6%
-30.6%
ROE
101.2%
-56.4%
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
LLY
Mediana dei peer
Debt / Equity (Debito / Patrimonio Netto)
1.5
0.0
Current Ratio (Rapporto corrente)
1.6
1.6
Quick Ratio
0.7
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
LLY
Mediana dei peer
Revenue YoY (Ricavi YoY)
44.7%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
31.7%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
21.6%
—
EPS YoY
96.0%
—
Net Income YoY (Utile Netto YoY)
94.9%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
LLY
Mediana dei peer
Payout Ratio (Rapporto di Distribuzione Utili)
26.1%
—
Dividendi Rendimento, payout ratio, storico dividendi, CAGR 5Y
Dividend Yield
—
Rapporto di Distribuzione Utili
26.1%
CAGR Dividendi 5Y
—
| Data ex-dividendo | Importo |
|---|---|
| 14 Agosto 2026 | $1,7300 |
| 15 Maggio 2026 | $1,7300 |
| 13 Febbraio 2026 | $1,7300 |
| 14 Novembre 2025 | $1,5000 |
| 15 Agosto 2025 | $1,5000 |
| 16 Maggio 2025 | $1,5000 |
| 14 Febbraio 2025 | $1,5000 |
| 15 Novembre 2024 | $1,3000 |
| 15 Agosto 2024 | $1,3000 |
| 15 Maggio 2024 | $1,3000 |
| 14 Febbraio 2024 | $1,3000 |
| 14 Novembre 2023 | $1,1300 |
| 14 Agosto 2023 | $1,1300 |
| 12 Maggio 2023 | $1,1300 |
| 14 Febbraio 2023 | $1,1300 |
| 14 Novembre 2022 | $0,9800 |
| 12 Agosto 2022 | $0,9800 |
| 13 Maggio 2022 | $0,9800 |
| 14 Febbraio 2022 | $0,9800 |
| 12 Novembre 2021 | $0,8500 |
LLY Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
38 analisti
- Acquisto forte 11 28,9%
- Compra 19 50,0%
- Mantieni 7 18,4%
- Vendi 1 2,6%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
27 analisti · 2026-08-15
Mediana
$1344.00
Ora
$1287.95
Basso
$850.00
Alto
$1600.00
Target mediano
$1344.00
+4,4%
Target medio
$1299.01
+0,9%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
1.2%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $8.38 | $6.07 | 2.3% |
| 31 Marzo 2026 | $8.55 | $6.73 | 1.8% |
| 31 Dicembre 2025 | $7.54 | $6.74 | 0.80% |
| 30 Settembre 2025 | $7.02 | $5.75 | 1.3% |
| 30 Giugno 2025 | $6.31 | $5.51 | 0.80% |
| 31 Marzo 2025 | $3.34 | $3.05 | 0.29% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
| JNJ | — | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 15
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B | $19.97B | $21.22B | $19.96B | $19.62B | |
| Cost of Revenue | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B | $5.48B | $4.72B | $4.68B | $4.45B | $5.71B | $5.04B | $4.93B | |
| R&D Expense | · | · | · | $7.19B | $6.93B | $5.98B | $5.59B | $5.05B | $5.10B | $5.31B | $4.80B | $4.73B | |
| SG&A Expense | $11.09B | $8.59B | $7.40B | $6.44B | $6.43B | $6.12B | $6.21B | $5.98B | $5.98B | $6.53B | $6.53B | $6.62B | |
| Interest Expense | · | · | $486M | $332M | $340M | $360M | $401M | $242M | $225M | $185M | $161M | $149M | |
| Interest Income | · | $175M | $174M | $63M | $25M | $33M | $80M | $159M | $166M | $109M | $87M | $121M | |
| Other Non-op | $-571M | $-219M | $97M | $-14M | $51M | $-196M | $-57M | $-12M | $111M | $196M | $342M | $368M | |
| Pretax Income | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B | $7.23B | $5.27B | $3.68B | $2.30B | $3.37B | $2.79B | $3.00B | |
| Income Tax | $5.09B | $2.09B | $1.31B | $562M | $574M | $1.04B | $628M | $530M | $2.39B | $636M | $382M | $610M | |
| Net Income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | $-204M | $2.74B | $2.41B | $2.39B | |
| EPS (Basic) | $23.00 | $11.76 | $5.82 | $6.93 | $6.15 | $6.82 | $8.93 | $3.14 | $-0.19 | $2.59 | $2.27 | $2.23 | |
| EPS (Diluted) | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 | $8.89 | $3.13 | $-0.19 | $2.58 | $2.26 | $2.23 | |
| Shares (Basic) | 897,300,000 | 900,600,000 | 900,200,000 | 901,736,000 | 906,963,000 | 907,634,000 | 931,059,000 | 1,027,721,000 | 1,052,023,000 | 1,058,324,000 | 1,061,913,000 | 1,069,932,000 | |
| Shares (Diluted) | 899,300,000 | 904,100,000 | 903,300,000 | 904,619,000 | 911,681,000 | 912,505,000 | 935,684,000 | 1,033,667,000 | 1,052,023,000 | 1,061,825,000 | 1,065,720,000 | 1,074,286,000 | |
| EBITDA | $2.00B | $1.77B | $1.53B | $1.52B | $1.55B | $1.32B | $1.23B | $1.61B | $1.57B | $1.50B | $1.43B | $1.38B |
Stato Patrimoniale 28
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B | $3.66B | $2.34B | $7.32B | $6.54B | $4.58B | $3.67B | $3.87B | |
| Short-term Investments | · | $155M | $109M | $145M | $90M | $24M | $101M | $88M | $1.50B | $1.46B | $785M | $955M | |
| Receivables | $17.76B | $11.01B | $9.09B | $6.90B | $6.67B | $5.88B | $4.55B | $4.59B | $4.55B | $4.03B | $3.51B | $3.23B | |
| Inventory | $13.74B | $7.59B | $5.77B | $4.31B | $3.89B | $3.98B | $3.19B | $3.10B | $4.46B | $3.56B | $3.45B | $2.74B | |
| Prepaid Expense | $14.31B | $8.34B | $5.54B | $2.95B | $2.53B | $2.87B | $2.54B | $2.04B | $1.45B | $735M | $604M | $560M | |
| Other Current Assets | $147M | $266M | $150M | $7M | · | · | · | · | · | · | · | · | |
| Current Assets | $55.63B | $32.74B | $25.73B | $18.03B | $18.45B | $17.46B | $13.71B | $20.55B | $19.20B | $15.10B | $12.57B | $11.93B | |
| PP&E (Net) | $24.68B | $17.10B | $12.91B | $10.14B | $8.99B | $8.68B | $7.87B | $8.00B | $8.83B | $8.25B | $8.05B | $7.96B | |
| PP&E (Gross) | · | $28.89B | $24.01B | $20.38B | $18.96B | $18.25B | $17.03B | $16.66B | $18.09B | $16.78B | $16.66B | $16.03B | |
| Accum. Depreciation | $12.56B | $11.79B | $11.10B | $10.23B | $9.98B | $9.57B | $9.16B | $8.67B | $9.26B | $8.53B | $8.61B | $8.07B | |
| Goodwill | $5.90B | $5.77B | $4.94B | $4.07B | $3.89B | $3.77B | $3.68B | $1.37B | $4.37B | $3.97B | $4.04B | $1.76B | |
| Intangibles | $6.52B | $6.17B | $6.91B | $7.21B | $7.69B | $7.45B | $6.62B | $1.07B | $4.03B | $4.36B | $5.03B | $2.88B | |
| Other Non-current Assets | $6.99B | $5.72B | $4.99B | $4.34B | $4.08B | $3.48B | $2.87B | $1.82B | $1.71B | $1.91B | $2.22B | $1.80B | |
| Total Assets | $112.48B | $78.72B | $64.01B | $49.49B | $48.81B | $46.63B | $39.29B | $43.91B | $44.98B | $38.81B | $35.57B | $36.31B | |
| Accounts Payable | $5.38B | $3.23B | $2.60B | $1.93B | $1.67B | $1.61B | $1.41B | $1.21B | $1.41B | $1.35B | $1.34B | $1.13B | |
| Short-term Debt | $0 | $4.34B | $6.19B | $1.50B | $0 | $0 | $1.49B | $499M | $2.70B | $1.30B | $0 | $2.68B | |
| Current Liabilities | $35.23B | $28.38B | $27.29B | $17.14B | $15.05B | $12.48B | $11.78B | $11.89B | $14.54B | $10.99B | $8.23B | $9.74B | |
| Capital Leases | $1.14B | $971M | $948M | · | · | · | $487M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | $87M | $1.73B | $2.10B | $2.19B | $1.31B | · | · | · | · | |
| Other Non-current Liabilities | $3.97B | $3.48B | $2.24B | $1.82B | $1.64B | $1.71B | $1.50B | $1.36B | $1.55B | $2.23B | $1.75B | $2.28B | |
| Long-term Debt | · | $29.47B | $19.10B | $14.82B | $16.74B | $16.35B | $13.64B | · | · | $9.01B | $7.98B | · | |
| Total Debt | $40.87B | $32.86B | $24.51B | $16.24B | $15.35B | $16.59B | $15.31B | $12.14B | $12.64B | $9.67B | $7.97B | $8.05B | |
| Common Stock | $590M | $592M | $594M | $594M | $596M | $598M | $599M | $661M | $688M | $688M | $691M | $695M | |
| Retained Earnings | $24.47B | $13.54B | $10.31B | $10.04B | $8.96B | $7.83B | $4.92B | $11.40B | $13.89B | $16.05B | $16.01B | $16.48B | |
| Treasury Stock | · | $50M | $44M | $50M | $53M | $56M | $61M | $69M | $76M | $80M | $90M | $91M | |
| AOCI | $-2.88B | $-4.32B | $-4.33B | $-3.84B | $-4.34B | $-6.50B | $-6.52B | $-5.73B | $-5.72B | $-5.27B | $-4.58B | $-3.99B | |
| Stockholders' Equity | $26.54B | $14.27B | $10.77B | $10.65B | $8.98B | $5.64B | $2.61B | $9.83B | $11.59B | $14.01B | $14.57B | $15.37B | |
| Liabilities + Equity | $112.48B | $78.72B | $64.01B | $49.49B | $48.81B | $46.63B | $39.29B | $43.91B | $44.98B | $38.81B | $35.57B | $36.31B |
Flusso di cassa 15
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2.00B | $1.77B | $1.53B | $1.52B | $1.55B | $1.32B | $1.23B | $1.61B | $1.57B | $1.50B | $1.43B | $1.38B | |
| Stock-based Comp | $626M | $646M | $629M | $371M | $343M | $308M | $312M | $280M | $281M | $255M | $218M | $156M | |
| Deferred Tax | $-1.71B | $-2.68B | $-2.34B | $-2.19B | $-802M | $-134M | $62M | $248M | $-832M | $440M | $-748M | $37M | |
| Amort. of Intangibles | $488M | $553M | $506M | $580M | $629M | $428M | $226M | $361M | $462M | $688M | $632M | $536M | |
| Other Non-cash | $-4.74B | $-1.50B | $-815M | $1.13B | $591M | $-1.19B | $-5.09B | $77M | $4.76B | $-78M | $-533M | $405M | |
| Operating Cash Flow | $16.81B | $8.82B | $4.24B | $7.59B | $7.37B | $6.50B | $4.84B | $5.52B | $5.62B | $4.85B | $2.96B | $4.46B | |
| Investing Cash Flow | $-10.97B | $-9.30B | $-7.15B | $-3.76B | $-2.87B | $-2.26B | $-8.08B | $1.91B | $-3.78B | $-3.14B | $27M | $-3.91B | |
| Debt Issued | $13.17B | $11.42B | $3.96B | $0 | $2.41B | $2.06B | $6.56B | $2.48B | $2.23B | $1.21B | $4.45B | $993M | |
| Net Debt Issued | $12.39B | $10.75B | $3.96B | $-1.56B | $505M | $1.79B | $3.69B | $1.47B | $1.60B | $1.21B | $2.50B | $-42M | |
| Stock Repurchased | $4.11B | $2.50B | $750M | $1.50B | $1.25B | $500M | $4.40B | $4.15B | $300M | $600M | $750M | $800M | |
| Net Stock Activity | $-4.11B | $-2.50B | $-750M | $-1.50B | $-1.25B | $-500M | $-4.40B | $-4.15B | $-300M | $-600M | $-750M | $-800M | |
| Dividends Paid | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B | $2.69B | $2.41B | $2.31B | $2.19B | $2.16B | $2.13B | $2.10B | |
| Financing Cash Flow | $-2.21B | $1.23B | $3.50B | $-5.41B | $-4.13B | $-3.14B | $-2.32B | $-5.90B | $143M | $-560M | $-3.11B | $-166M | |
| Net Change in Cash | $4.00B | $449M | $752M | $-1.75B | $161M | $1.32B | $-5.66B | $1.46B | $1.95B | $916M | $-205M | $41M | |
| Taxes Paid | $10.81B | $6.56B | $5.56B | · | · | · | · | · | · | · | · | · |
Redditività 5
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 13.2% | -0.89% | 12.9% | 12.1% | 12.2% | |
| Pretax Margin | 39.5% | 28.1% | 19.2% | 23.8% | 21.7% | 29.5% | 23.6% | 15.5% | 9.6% | 15.9% | 14.0% | 15.3% | |
| EBITDA Margin | 3.1% | 3.9% | 4.5% | 5.3% | 5.5% | 5.4% | 5.5% | 6.6% | 6.9% | 7.0% | 7.1% | 7.0% | |
| ROA | 21.6% | 14.8% | 9.2% | 12.7% | 11.7% | 14.4% | 20.0% | 7.3% | -0.49% | 7.4% | 6.7% | 6.6% | |
| ROE | 101.2% | 84.8% | 48.9% | 63.6% | 76.3% | 150.2% | 133.8% | 30.2% | -1.6% | 19.2% | 16.1% | 14.5% |
Liquidità e Solvibilità 4
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | 0.9 | 1.1 | 1.2 | 1.4 | 1.2 | 1.7 | 1.3 | 1.4 | 1.5 | 1.1 | |
| Quick Ratio | 0.7 | 0.5 | 0.4 | 0.5 | 0.7 | 0.8 | 0.6 | 1.1 | 0.9 | 0.9 | 1.0 | 0.7 | |
| Debt / Equity | 1.5 | 2.3 | 2.3 | 1.5 | 1.7 | 2.9 | 5.9 | 1.2 | 1.1 | 0.7 | 0.5 | 0.5 | |
| LT Debt / Equity | 1.5 | 2.0 | 1.7 | 1.4 | 1.7 | 2.9 | 5.3 | 1.2 | 0.9 | 0.6 | 0.5 | 0.3 |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.5 | 0.6 | 0.6 | 0.5 | |
| Inventory Turnover | 1.0 | 1.3 | 1.4 | 1.6 | 1.9 | 1.5 | 1.5 | 1.5 | 1.5 | 1.6 | 1.6 | 1.7 | |
| Receivables Turnover | 4.5 | 4.5 | 4.3 | 4.2 | 4.5 | 4.7 | 4.9 | 5.0 | 5.3 | 5.6 | 5.9 | 5.9 |
Tassi di Crescita 10
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 44.7% | 32.0% | 19.6% | 0.79% | 15.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 31.7% | 16.7% | 11.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 21.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 96.0% | 101.9% | -15.9% | 12.8% | -9.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 49.3% | 24.1% | -5.1% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 27.6% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 94.9% | 102.1% | -16.1% | 11.9% | -9.9% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 49.0% | 23.8% | -5.4% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 27.2% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 14.9% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 6
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B | $19.97B | $21.22B | $19.96B | $19.62B | |
| Net Income TTM | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | $-204M | $2.74B | $2.41B | $2.39B | |
| P/E | 46.8 | 65.9 | 100.5 | 53.0 | 45.1 | 24.9 | 14.8 | 37.0 | -444.5 | 28.5 | 37.3 | 30.9 | |
| Earnings Yield | 2.1% | 1.5% | 0.99% | 1.9% | 2.2% | 4.0% | 6.8% | 2.7% | -0.22% | 3.5% | 2.7% | 3.2% | |
| Payout Ratio | 26.1% | 44.2% | 77.6% | 56.6% | 55.3% | 43.4% | 29.0% | 71.5% | -1074.0% | 78.8% | 88.3% | 87.9% | |
| Annual Payout | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B | $2.69B | $2.41B | $2.31B | $2.19B | $2.16B | $2.13B | $2.10B |
Conto Economico 15
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.97B | $19.80B | $19.29B | $17.60B | $15.56B | $12.73B | $13.53B | $11.44B | $11.30B | $8.77B | $9.35B | $9.50B | $8.31B | $6.96B | $7.30B | $6.94B | |
| Cost of Revenue | $3.27B | $3.58B | $3.37B | $3.01B | $2.45B | $2.23B | $2.40B | $2.17B | $2.17B | $1.67B | $1.79B | $1.86B | $1.81B | $1.63B | $1.55B | $1.58B | |
| R&D Expense | · | · | · | · | · | · | · | · | · | · | · | · | $2.36B | $1.99B | · | $1.80B | |
| SG&A Expense | $3.43B | $2.93B | $3.13B | $2.74B | $2.75B | $2.47B | $2.42B | $2.10B | $2.12B | $1.95B | $1.93B | $1.80B | $1.93B | $1.75B | $1.64B | $1.61B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $180M | · | $125M | $120M | $103M | · | $82M | |
| Interest Income | · | · | · | $65M | $40M | $48M | · | $48M | $37M | $46M | · | $49M | $46M | $34M | $26M | $20M | |
| Other Non-op | $269M | $-65M | $-287M | $-179M | $-90M | $-239M | $-219M | $-21M | $-8M | $29M | $108M | $-100.0K | $-13M | $2M | $-31M | $-19M | |
| Pretax Income | $9.25B | $8.85B | $8.27B | $7.23B | $6.78B | $3.46B | $5.04B | $1.59B | $3.52B | $2.54B | $2.51B | $427M | $2.09B | $1.53B | $2.10B | $1.57B | |
| Income Tax | $2.15B | $1.45B | $1.63B | $1.65B | $1.12B | $697M | $628M | $618M | $550M | $293M | $319M | $485M | $326M | $185M | $159M | $114M | |
| Net Income | $7.09B | $7.40B | $6.64B | $5.58B | $5.66B | $2.76B | $4.41B | $970M | $2.97B | $2.24B | $2.19B | $-57M | $1.76B | $1.34B | $1.94B | $1.45B | |
| EPS (Basic) | $7.95 | $8.27 | $7.41 | $6.22 | $6.30 | $3.07 | $4.90 | $1.08 | $3.29 | $2.49 | $2.43 | $-0.06 | $1.96 | $1.49 | $2.15 | $1.61 | |
| EPS (Diluted) | $7.94 | $8.26 | $7.39 | $6.21 | $6.29 | $3.06 | $4.88 | $1.07 | $3.28 | $2.48 | $2.42 | $-0.06 | $1.95 | $1.49 | $2.14 | $1.61 | |
| Shares (Basic) | 892,400,000 | 894,500,000 | -1,796,200,000 | 896,900,000 | 897,900,000 | 898,700,000 | -1,802,100,000 | 901,000,000 | 900,900,000 | 900,800,000 | -1,800,300,000 | 899,800,000 | 899,700,000 | 901,000,000 | -1,802,964,000 | 900,700,000 | |
| Shares (Diluted) | 893,700,000 | 895,900,000 | -1,799,900,000 | 898,800,000 | 899,800,000 | 900,600,000 | -1,808,900,000 | 905,000,000 | 904,200,000 | 903,800,000 | -1,802,500,000 | 899,800,000 | 902,700,000 | 903,300,000 | -1,808,481,000 | 903,800,000 | |
| EBITDA | · | $509M | · | · | · | $463M | · | · | · | $401M | · | · | · | $362M | · | · |
Stato Patrimoniale 26
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.95B | $5.28B | $7.27B | $9.79B | $3.38B | $3.09B | $3.27B | $3.37B | $3.22B | $2.46B | · | $2.38B | $2.69B | $3.55B | · | $2.62B | |
| Short-term Investments | · | · | · | $122M | $170M | $127M | · | $149M | $140M | $126M | · | $113M | $135M | $123M | · | $125M | |
| Receivables | $20.08B | $18.43B | $17.76B | $16.11B | $14.17B | $12.04B | $11.01B | $10.29B | $11.03B | $7.89B | · | $8.17B | $7.52B | $7.53B | · | $6.72B | |
| Inventory | $16.79B | $14.53B | $13.74B | $12.18B | $11.01B | $9.31B | $7.59B | $7.46B | $6.48B | $6.10B | · | $4.90B | $4.80B | $4.54B | · | $3.83B | |
| Prepaid Expense | $15.37B | $13.63B | $14.31B | $20.25B | $18.02B | $14.65B | $8.34B | $8.25B | $7.14B | $6.35B | · | $5.25B | $4.53B | $3.58B | · | $2.74B | |
| Other Current Assets | $86M | $214M | $147M | $272M | $69M | $72M | $266M | $135M | $142M | $139M | · | · | · | · | · | · | |
| Current Assets | $64.67B | $54.84B | $55.63B | $62.07B | $49.85B | $41.26B | $32.74B | $31.42B | $30.20B | $25.19B | · | $23.01B | $21.33B | $20.81B | · | $17.64B | |
| PP&E (Net) | $29.29B | $26.54B | $24.68B | $22.32B | $20.53B | $18.47B | $17.10B | $16.17B | $14.83B | $13.62B | · | $11.86B | $11.28B | $10.55B | · | $9.31B | |
| Accum. Depreciation | $13.10B | · | $12.56B | $12.41B | $12.55B | $12.15B | $11.79B | $11.82B | $11.43B | $11.23B | · | $10.77B | $10.63B | $10.49B | · | $10.07B | |
| Goodwill | $8.85B | $6.13B | $5.90B | $5.90B | $5.77B | $5.77B | $5.77B | $5.77B | $5.77B | $4.94B | · | $4.09B | $4.08B | $4.07B | · | $3.89B | |
| Intangibles | $18.11B | $7.37B | $6.52B | $6.45B | $5.91B | $6.01B | $6.17B | $6.54B | $6.64B | $6.76B | · | $6.78B | $6.90B | $7.09B | · | $7.12B | |
| Other Non-current Assets | $7.48B | $7.23B | $6.99B | $6.43B | $6.23B | $6.07B | $5.72B | $5.12B | $4.90B | $4.71B | · | $4.91B | $4.67B | $4.49B | · | $4.54B | |
| Total Assets | $142.28B | $116.58B | $112.48B | $114.94B | $100.92B | $89.39B | $78.72B | $75.61B | $71.87B | $63.94B | · | $57.92B | $54.81B | $53.16B | · | $47.46B | |
| Accounts Payable | $6.11B | $5.03B | $5.38B | $4.26B | $4.08B | $3.44B | $3.23B | $2.89B | $2.92B | $2.47B | · | $2.44B | $2.47B | $2.02B | · | $1.68B | |
| Short-term Debt | · | · | $0 | · | · | · | $4.34B | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $47.74B | $36.63B | $35.23B | $40.14B | $39.02B | $30.07B | $28.38B | $24.67B | $27.12B | $18.60B | · | $22.00B | $18.91B | $16.01B | · | $15.65B | |
| Capital Leases | · | · | $1.14B | · | · | · | $971M | · | · | · | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $172M | |
| Other Non-current Liabilities | $7.34B | $4.08B | $3.97B | $3.78B | $2.34B | $2.29B | $3.48B | $2.24B | $2.47B | $2.27B | · | $1.91B | $1.95B | $1.82B | · | $1.85B | |
| Total Debt | $47.86B | $39.37B | · | $40.87B | $34.18B | $34.50B | · | $29.05B | $23.73B | $24.56B | · | $17.92B | $18.16B | $18.88B | · | $14.14B | |
| Common Stock | $588M | $590M | $590M | $591M | $592M | $593M | $592M | $594M | $594M | $594M | · | $594M | $594M | $594M | · | $594M | |
| Retained Earnings | $31.89B | $29.51B | $24.47B | $22.25B | $17.38B | $15.10B | $13.54B | $13.63B | $13.18B | $12.55B | · | $10.31B | $10.37B | $10.64B | · | $10.01B | |
| Treasury Stock | · | · | · | $62M | $55M | $50M | · | $33M | $33M | $33M | · | $45M | $45M | $45M | · | $50M | |
| AOCI | $-2.76B | $-2.83B | $-2.88B | $-3.21B | $-3.72B | $-3.77B | $-4.32B | $-4.27B | $-4.38B | $-4.30B | · | $-3.78B | $-3.79B | $-3.78B | · | $-4.30B | |
| Stockholders' Equity | $33.88B | $31.20B | $26.54B | $23.79B | $18.27B | $15.76B | $14.27B | $14.24B | $13.56B | $12.81B | · | $11.22B | $11.06B | $11.19B | · | $10.07B | |
| Liabilities + Equity | $142.28B | $116.58B | $112.48B | $114.94B | $100.92B | $89.39B | $78.72B | $75.61B | $71.87B | $63.94B | · | $57.92B | $54.81B | $53.16B | · | $47.46B |
Flusso di cassa 13
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $534M | $509M | $586M | $470M | $478M | $463M | $485M | $467M | $414M | $401M | $387M | $411M | $366M | $362M | $375M | $363M | |
| Stock-based Comp | $201M | $161M | $136M | $151M | $185M | $154M | $142M | $133M | $211M | $159M | $121M | $216M | $162M | $131M | $93M | $85M | |
| Other Non-cash | · | $-2.73B | · | · | · | $-1.71B | · | · | · | $-1.64B | · | · | · | $-108M | · | · | |
| Operating Cash Flow | $10.69B | $5.33B | $3.22B | $8.84B | $3.09B | $1.67B | $2.47B | $3.71B | $1.47B | $1.17B | $-312M | $2.19B | $632M | $1.73B | $1.66B | $2.60B | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $617M | |
| Investing Cash Flow | $-15.40B | $-3.92B | $-2.80B | $-2.98B | $-1.83B | $-3.35B | $-1.92B | $-4.00B | $-2.20B | $-1.18B | $-2.92B | $-3.08B | $-459M | $-689M | $-944M | $-1.34B | |
| Debt Issued | $8.94B | $0 | $-200.0K | $6.71B | $0 | $6.46B | $-100.0K | $4.96B | $0 | $6.45B | $500.0K | $0 | $0 | $3.96B | $0 | $0 | |
| Net Debt Issued | · | $-750M | · | · | · | $6.46B | · | · | · | $6.45B | · | · | · | $3.96B | · | · | |
| Stock Repurchased | $1.60B | $2.36B | $1.51B | $708M | $692M | $1.20B | $2.05B | $446M | $0 | $0 | $0 | $0 | $0 | $750M | $0 | $0 | |
| Net Stock Activity | · | $-2.36B | · | · | · | $-1.20B | · | · | · | $0 | · | · | · | $-750M | · | · | |
| Dividends Paid | $1.55B | $1.55B | $1.35B | $1.35B | $1.35B | $1.35B | $1.17B | $1.17B | $1.17B | $1.17B | $1.02B | $1.02B | $1.02B | $1.02B | $884M | $882M | |
| Financing Cash Flow | $8.43B | $-3.47B | $-2.88B | $531M | $-1.24B | $1.38B | $-226M | $211M | $1.56B | $-311M | $3.55B | $572M | $-1.03B | $412M | $-1.14B | $-1.26B | |
| Net Change in Cash | $3.67B | $-1.99B | $-2.52B | $6.42B | $283M | $-175M | $-101M | $145M | $763M | $-358M | $438M | $-314M | $-851M | $1.48B | $-550M | $-6M |
Redditività 5
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 30.9% | 37.4% | · | 31.7% | 36.4% | 21.7% | · | 8.5% | 26.2% | 25.6% | · | -0.60% | 21.2% | 19.3% | · | 20.9% | |
| Pretax Margin | 40.2% | 44.7% | · | 41.1% | 43.6% | 27.2% | · | 13.9% | 31.1% | 28.9% | · | 4.5% | 25.1% | 22.0% | · | 22.6% | |
| EBITDA Margin | · | 2.6% | · | · | · | 3.6% | · | · | · | 4.6% | · | · | · | 5.2% | · | · | |
| ROA | 5.8% | 7.2% | · | 5.9% | 6.6% | 3.6% | · | 1.5% | 4.7% | 3.8% | · | -0.11% | 3.5% | 2.7% | · | 3.0% | |
| ROE | 27.2% | 31.5% | · | 29.4% | 35.6% | 19.3% | · | 7.6% | 24.1% | 18.7% | · | -0.54% | 18.0% | 13.1% | · | 16.3% |
Liquidità e Solvibilità 4
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.4 | 1.5 | · | 1.5 | 1.3 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.0 | 1.1 | 1.3 | · | 1.1 | |
| Quick Ratio | 0.6 | 0.6 | · | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.5 | 0.6 | · | 0.5 | 0.5 | 0.7 | · | 0.6 | |
| Debt / Equity | 1.4 | 1.3 | · | 1.7 | 1.9 | 2.2 | · | 2.0 | 1.7 | 1.9 | · | 1.6 | 1.6 | 1.7 | · | 1.4 | |
| LT Debt / Equity | 1.4 | 1.3 | · | 1.7 | 1.9 | 2.2 | · | 2.0 | 1.7 | 1.9 | · | 1.6 | 1.6 | 1.7 | · | 1.4 |
Efficienza 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.2 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.4 | 0.4 | 0.3 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.2 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.3 | 1.2 | 1.0 | · | 1.1 |
Valutazione (TTM) 5
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.93B | $65.69B | · | $57.33B | $51.03B | $44.24B | · | $41.01B | $37.88B | $33.54B | · | $31.71B | $28.70B | $28.20B | · | $28.01B | |
| Net Income TTM | $25.73B | $21.40B | · | $14.97B | $12.36B | $8.94B | · | $6.12B | $6.92B | $5.29B | · | $4.50B | $5.51B | $5.65B | · | $5.42B | |
| P/E | 41.8 | 38.6 | · | 45.9 | 56.9 | 83.5 | · | 130.9 | 118.4 | 132.8 | · | 107.6 | 76.9 | 54.9 | · | 54.1 | |
| Earnings Yield | 2.4% | 2.6% | · | 2.2% | 1.8% | 1.2% | · | 0.76% | 0.84% | 0.75% | · | 0.93% | 1.3% | 1.8% | · | 1.8% | |
| Payout Ratio | · | 20.9% | · | · | · | 48.8% | · | · | · | 52.1% | · | · | · | 75.6% | · | · |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B |
| Utile netto | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B |
| EPS Diluito | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 1.5 | 2.3 | 2.3 | 1.5 | 1.7 |
| Rapporto corrente | 1.6 | 1.2 | 0.9 | 1.1 | 1.2 |
| Quick Ratio | 0.7 | 0.5 | 0.4 | 0.5 | 0.7 |
Ultime notizie Notizie recenti che menzionano questa società
- Three Center-Stage AI Players Join Eli Lilly On Elite Screen
- Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?
- Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?
- SPYM, GOOGL, LLY, BRK.B: Large Inflows Detected at ETF
- Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk
- "Pubblicità ingannevole!" accusa Novo Nordisk in una nuova causa esplosiva sui GLP-1 contro Eli Lilly. Ecco cosa significa per entrambi i titoli.
- Ozempic-maker sues rival, accusing it of false advertising
- The market for psychedelic drugs to treat mental health conditions gets a big buy signal
- Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma’s Latest Psychedelic Foray
- AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 5.055 filer · $618.4B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 386 (+102 vs trimestre precedente) | 87 (-139 vs trimestre precedente) | 2.157 (+233 vs trimestre precedente) | 1.477 (-243 vs trimestre precedente) | +108.0M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| LILLY ENDOWMENT INC | $108.400.858.723 | 90.376.978 | 17,53% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $64.204.130.146 | 53.528.868 | 10,38% | Azioni |
| STATE STREET CORP | $43.438.261.820 | 36.215.754 | 7,02% | Azioni |
| Capital Research Global Investors | $25.037.481.632 | 20.873.140 | 4,05% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $25.019.170.646 | 20.859.217 | 4,05% | Azioni |
| FMR LLC | $23.272.664.162 | 19.403.104 | 3,76% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $21.252.395.665 | 17.790.304 | 3,44% | Azioni |
| Capital World Investors | $19.076.022.904 | 15.902.642 | 3,08% | Azioni |
| NORGES BANK | $13.759.156.895 | 11.471.413 | 2,22% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $12.172.183.865 | 10.148.307 | 1,97% | Azioni |
| PRIMECAP MANAGEMENT CO/CA/ | $11.002.256.246 | 9.172.904 | 1,78% | Azioni |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $8.853.660.913 | 7.381.557 | 1,43% | Azioni |
| UBS Group AG | $8.756.297.182 | 7.300.382 | 1,42% | Opzione Call |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $7.198.575.852 | 6.001.664 | 1,16% | Azioni |
| Capital International Investors | $6.879.841.625 | 5.734.768 | 1,11% | Azioni |
| JENNISON ASSOCIATES LLC | $6.415.075.179 | 5.348.436 | 1,04% | Azioni |
| Fisher Asset Management, LLC | $6.073.333.633 | 5.063.516 | 0,98% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $5.508.155.583 | 4.592.311 | 0,89% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $4.288.683.267 | 3.575.603 | 0,69% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $3.916.450.563 | 4.258.076 | 0,63% | Azioni |
| JANE STREET GROUP, LLC | $3.018.245.652 | 2.516.400 | 0,49% | Opzione Put |
| AMERICAN CENTURY COMPANIES INC | $2.824.462.145 | 2.354.837 | 0,46% | Azioni |
| CITADEL ADVISORS LLC | $2.817.700.956 | 2.349.200 | 0,46% | Opzione Put |
| Swiss National Bank | $2.716.888.865 | 2.265.150 | 0,44% | Azioni |
| UBS Group AG | $2.674.269.518 | 2.229.617 | 0,43% | Azioni |
| BlackRock, Inc. | $2.610.637.358 | 2.176.565 | 0,42% | Azioni |
| VICTORY CAPITAL MANAGEMENT INC | $2.568.591.611 | 2.141.447 | 0,42% | Azioni |
| JANE STREET GROUP, LLC | $2.536.674.507 | 2.114.900 | 0,41% | Opzione Call |
| Mitsubishi UFJ Asset Management Co., Ltd. | $2.415.287.393 | 2.013.696 | 0,39% | Azioni |
| GOLDMAN SACHS GROUP INC | $2.358.324.528 | 1.966.204 | 0,38% | Azioni |
| Sumitomo Mitsui Trust Group, Inc. | $2.273.837.414 | 1.895.765 | 0,37% | Azioni |
| CITADEL ADVISORS LLC | $2.256.727.545 | 1.881.500 | 0,36% | Opzione Call |
| Legal & General Group Plc | $2.202.867.142 | 1.836.595 | 0,36% | Azioni |
| FIFTH THIRD BANCORP | $2.099.946.659 | 1.750.788 | 0,34% | Azioni |
| BANK OF AMERICA CORP /DE/ | $2.060.238.592 | 1.717.681 | 0,33% | Azioni |
| CANADA PENSION PLAN INVESTMENT BOARD | $2.057.106.410 | 1.715.070 | 0,33% | Azioni |
| Vanguard Global Advisers, LLC | $2.048.187.448 | 1.707.634 | 0,33% | Azioni |
| National Pension Service | $2.018.379.214 | 1.682.782 | 0,33% | Azioni |
| NEUBERGER BERMAN GROUP LLC | $1.973.413.342 | 1.645.037 | 0,32% | Azioni |
| AMERIPRISE FINANCIAL INC | $1.955.279.981 | 1.630.180 | 0,32% | Azioni |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.867.073.519 | 1.556.634 | 0,30% | Azioni |
| VANGUARD GROUP INC | $1.858.925.581 | 1.729.748 | 0,30% | Azioni |
| SAPIENT CAPITAL LLC | $1.736.223.301 | 1.447.540 | 0,28% | Azioni |
| California Public Employees Retirement System | $1.727.998.411 | 1.440.683 | 0,28% | Azioni |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $1.604.453.190 | 1.337.665 | 0,26% | Azioni |
| RHUMBLINE ADVISERS | $1.599.208.304 | 1.333.307 | 0,26% | Azioni |
| LPL Financial LLC | $1.529.042.537 | 1.274.807 | 0,25% | Azioni |
| US BANCORP \DE\ | $1.525.382.299 | 1.271.756 | 0,25% | Azioni |
| PeakShares LLC | $1.459.706.000 | 1.217 | 0,24% | Azioni |
| ENVESTNET ASSET MANAGEMENT INC | $1.410.361.452 | 1.175.866 | 0,23% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $1.378.916.702 | 1.149.643 | 0,22% | Azioni |
| APG Asset Management N.V. | $1.269.741.378 | 1.210.321 | 0,21% | Azioni |
| TD Asset Management Inc | $1.203.590.823 | 1.003.469 | 0,19% | Azioni |
| COMERICA BANK | $1.187.462.066 | 1.104.945 | 0,19% | Azioni |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $1.182.373.533 | 1.285.510 | 0,19% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $1.153.247.147 | 961.496 | 0,19% | Azioni |
| NORDEA INVESTMENT MANAGEMENT AB | $1.140.281.246 | 946.590 | 0,18% | Azioni |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $1.117.172.877 | 1.214.622 | 0,18% | Azioni |
| Bank Julius Baer & Co. Ltd, Zurich | $1.100.986.977 | 913.248 | 0,18% | Azioni |
| Ensign Peak Advisors, Inc | $1.073.804.101 | 895.262 | 0,17% | Azioni |
| PNC Financial Services Group, Inc. | $1.055.920.599 | 880.352 | 0,17% | Azioni |
| NEW YORK STATE COMMON RETIREMENT FUND | $1.038.211.015 | 865.587 | 0,17% | Azioni |
| Caisse de depot et placement du Quebec | $966.511.489 | 805.809 | 0,16% | Azioni |
| Robeco Institutional Asset Management B.V. | $910.055.515 | 758.740 | 0,15% | Azioni |
| Pictet Asset Management Holding SA | $905.835.797 | 754.985 | 0,15% | Azioni |
| BARCLAYS PLC | $904.852.390 | 754.402 | 0,15% | Azioni |
| Grantham, Mayo, Van Otterloo & Co. LLC | $892.337.542 | 743.966 | 0,14% | Azioni |
| PRUDENTIAL FINANCIAL INC | $879.194.184 | 733.010 | 0,14% | Azioni |
| CITADEL ADVISORS LLC | $874.462.433 | 729.065 | 0,14% | Azioni |
| JONES FINANCIAL COMPANIES LLLP | $874.355.284 | 723.732 | 0,14% | Azioni |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $871.024.867 | 726.199 | 0,14% | Azioni |
| AVIVA PLC | $861.503.791 | 718.261 | 0,14% | Azioni |
| LAZARD ASSET MANAGEMENT LLC | $828.834.772 | 691.024 | 0,13% | Azioni |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $819.673.670 | 683.386 | 0,13% | Azioni |
| CIBC Bancorp USA Inc. | $819.454.832 | 683.299 | 0,13% | Azioni |
| POLEN CAPITAL MANAGEMENT LLC | $799.914.391 | 666.912 | 0,13% | Azioni |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $792.908.390 | 661.071 | 0,13% | Azioni |
| Korea Investment CORP | $790.364.399 | 658.950 | 0,13% | Azioni |
| Bahl & Gaynor LLC | $786.973.674 | 656.123 | 0,13% | Azioni |
| ROYAL LONDON ASSET MANAGEMENT LTD | $774.668.656 | 645.864 | 0,13% | Azioni |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $729.268.278 | 610.128 | 0,12% | Azioni |
| GOLDMAN SACHS GROUP INC | $697.588.488 | 581.600 | 0,11% | Opzione Put |
| MACKENZIE FINANCIAL CORP | $696.221.138 | 580.460 | 0,11% | Azioni |
| Ninety One UK Ltd | $684.160.837 | 570.405 | 0,11% | Azioni |
| WOLVERINE TRADING, LLC | $675.581.649 | 929.900 | 0,11% | Opzione Put |
| WOLVERINE TRADING, LLC | $665.773.764 | 916.400 | 0,11% | Opzione Call |
| Quantinno Capital Management LP | $656.743.405 | 547.546 | 0,11% | Azioni |
| Goelzer Investment Management, Inc. | $644.679.302 | 537.488 | 0,10% | Azioni |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $631.148.000 | 526.202 | 0,10% | Azioni |
| PARNASSUS INVESTMENTS, LLC | $630.257.285 | 525.464 | 0,10% | Azioni |
| BANK OF MONTREAL /CAN/ | $623.256.213 | 519.627 | 0,10% | Azioni |
| Employees Provident Fund Board | $621.615.392 | 518.259 | 0,10% | Azioni |
| CITIGROUP INC | $614.947.761 | 512.700 | 0,10% | Opzione Put |
| Assenagon Asset Management S.A. | $600.944.416 | 501.025 | 0,10% | Azioni |
| Aberdeen Group plc | $582.286.083 | 485.469 | 0,09% | Azioni |
| Clearbridge Investments, LLC | $579.491.277 | 483.139 | 0,09% | Azioni |
| PFA Pension, Forsikringsaktieselskab | $579.482.599 | 483.132 | 0,09% | Azioni |
| AMF Tjanstepension AB | $573.419.896 | 478.077 | 0,09% | Azioni |
| DEUTSCHE BANK AG\ | $572.292.432 | 477.137 | 0,09% | Azioni |
| STOREBRAND ASSET MANAGEMENT AS | $565.821.507 | 471.742 | 0,09% | Azioni |
Insider aziendali 83 insider · 48 dirigenti · 30 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| David A Ricks | President, Chair, and CEO | 12 Agosto 2025 P | 546.601 | 0 | 0 | $0 |
| Lucas Montarce | EVP & CFO | 15 Agosto 2025 P | 14.685 | 0 | 0 | $0 |
| Anat Ashkenazi | EVP & CFO | 12 Febbraio 2024 A | 42.330 | 0 | 0 | $0 |
| Derica W Rice | EVP-Global Services and CFO | 01 Febbraio 2017 M | 38.292 | 0 | 0 | $0 |
| Charles E Golden | Exec. Vice President and CFO | 28 Aprile 2006 F | 85.249 | 0 | 0 | $0 |
| Maria A Crowe | President, Mfg. Operations | 01 Febbraio 2017 M | 113.581 | 0 | 0 | $0 |
| Frank M Deane | President, Mfg. Operations | 01 Febbraio 2012 M | 33.995 | 0 | 0 | $0 |
| Deirdre P Connelly | President, U.S. Operations | 27 Gennaio 2009 A | 53.681 | 0 | 0 | $0 |
| Lorenzo Tallarigo | President, Internat'l Opers. | 31 Marzo 2008 F | 64.458 | 0 | 0 | $0 |
| Scott A Canute | President, Mfg. Operations | 01 Febbraio 2007 F | 25.367 | 0 | 0 | $0 |
| Patrik Jonsson | EVP & President, LLY Int'l | 17 Agosto 2026 S | 54.147 | 0 | 1 | $-7.638.150 |
| Melissa Seymour | EVP, Global Quality | 01 Agosto 2026 M | 1.067 | 0 | 0 | $0 |
| Ilya Yuffa | EVP&Pres, LLY USA&Global Capab | 10 Giugno 2026 S | 29.804 | 0 | 1 | $-2.876.925 |
| Edgardo Hernandez | EVP & Pres., Mfg. Operations | 05 Settembre 2025 G | 39.731 | 0 | 0 | $0 |
| Kenneth L. Custer | EVP & President, Card Met Hlth | 27 Agosto 2025 I | — | 0 | 0 | $0 |
| Jacob Van Naarden | EVP & Pres., Lilly Oncology | 13 Agosto 2025 P | 20.562 | 0 | 0 | $0 |
| Daniel Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | 12 Agosto 2025 P | 137.660 | 0 | 0 | $0 |
| Eric Dozier | EVP, Chief People Officer | 01 Marzo 2025 M | 9.839 | 0 | 0 | $0 |
| Diogo Rau | EVP & CIDO | 10 Febbraio 2025 A | 19.719 | 0 | 0 | $0 |
| Anne E. White | EVP & Pres, Lilly Neuroscience | 10 Febbraio 2025 A | 74.210 | 0 | 0 | $0 |
| Johna Norton | EVP, Global Quality | 03 Giugno 2024 S | 25.428 | 0 | 0 | $0 |
| Alonzo Weems | EVP, ERM & CECO | 12 Febbraio 2024 A | 7.951 | 0 | 0 | $0 |
| Michael B Mason | EVP & Pres., Lilly Diabetes | 10 Febbraio 2023 A | 39.284 | 0 | 0 | $0 |
| Leigh Ann Pusey | EVP, Corp. Affairs & Comm. | 10 Febbraio 2023 A | 31.641 | 0 | 0 | $0 |
| Stephen F Fry | SVP, HR & Diversity | 09 Febbraio 2022 A | 152.631 | 0 | 0 | $0 |
| Myles O'Neill | SVP & Pres., Mfg. Operations | 08 Febbraio 2021 A | 72.533 | 0 | 0 | $0 |
| Alfonso G Zulueta | SVP & President, Lilly Int'l | 08 Febbraio 2021 A | 56.947 | 0 | 0 | $0 |
| Melissa S Barnes | Chief Eth/Cmpl Ofcr & SVP, ERM | 08 Febbraio 2021 A | 34.616 | 0 | 0 | $0 |
| Michael J Harrington | Senior VP and General Counsel | 02 Gennaio 2020 A | 59.500 | 0 | 0 | $0 |
| Christi Shaw | SVP and Pres., Lilly Bio-Meds | 03 Maggio 2019 S | 500 | 0 | 0 | $0 |
| Enrique A Conterno | SVP&Pres, LillyDiab & LillyUSA | 04 Febbraio 2019 A | 157.962 | 0 | 0 | $0 |
| Jeffrey N Simmons | SVP&Pres. Elanco Animal Health | 01 Maggio 2018 M | 135.458 | 0 | 0 | $0 |
| Susan Mahony | SVP & Pres., Lilly Oncology | 16 Aprile 2018 S | 40.685 | 0 | 0 | $0 |
| Jan M Lundberg | EVP,Science&Tech and Pres. LRL | 09 Febbraio 2018 A | 198.126 | 0 | 0 | $0 |
| Fionnuala M Walsh | SVP, Global Quality | 01 Febbraio 2017 M | 67.144 | 0 | 0 | $0 |
| Barton R Peterson | Sr. VP, Corp. Affairs & Comm. | 01 Febbraio 2017 M | 108.312 | 0 | 0 | $0 |
| Jacques Tapiero | SVP&Pres., Emerging Markets | 28 Gennaio 2014 A | 55.384 | 0 | 0 | $0 |
| Arnold C Hanish | Chief Accounting Officer | 29 Agosto 2012 G | 17.611 | 0 | 0 | $0 |
| Bryce D. Carmine | EVP and Pres, Lilly Bio-Meds | 01 Febbraio 2012 M | 102.647 | 0 | 0 | $0 |
| Robert A Armitage | Sr. VP and General Counsel | 01 Febbraio 2012 M | 97.063 | 0 | 0 | $0 |
| Anne Nobles | Chief Eth/Cmpl Ofcr & SVP, ERM | 26 Gennaio 2012 A | 23.536 | 0 | 0 | $0 |
| Steven M Paul | EVP, Science and Technology | 01 Febbraio 2010 M | 38.897 | 0 | 0 | $0 |
| Anthony John Murphy | Senior VP, Human Resources | 02 Febbraio 2009 F | 15.231 | 0 | 0 | $0 |
| Gino Santini | Sr.VP, Corp. Strategy & BD | 02 Febbraio 2009 F | 102.174 | 0 | 0 | $0 |
| Alex M Azar II | Sr. VP, Corp. Affairs & Comm. | 27 Gennaio 2009 A | 5.000 | 0 | 0 | $0 |
| Sidney Taurel | Chairman | 31 Dicembre 2008 F | 341.806 | 0 | 0 | $0 |
| Gerhard N Mayr | EVP, Pharmaceutical Operations | 17 Febbraio 2004 A | — | 0 | 0 | $0 |
| Pedro P Granadillo | Senior Vice President | 17 Febbraio 2004 A | — | 0 | 0 | $0 |
| Juan R Luciano | Direttore | 17 Agosto 2026 A | 16.918 | 0 | 0 | $0 |
| Erik J Fyrwald | Direttore | 17 Agosto 2026 A | 75.418 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 1 partecipazione
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| ELI LILLY AND COMPANY, SHENANDOAH ACQUISITION CORPORATION ×15 depositi | 14 Agosto 2023 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 324 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| IHE · iShares Trust | 21,36% | 290.244 SH | 08 Agosto 2026 | Giornaliero |
| MEDI · Harbor ETF Trust | 20,10% | 5.929 NS | 30 Aprile 2026 | N-PORT |
| IYH · iShares Trust | 15,48% | 478.046 SH | 08 Agosto 2026 | Giornaliero |
| ELIL · Direxion Shares ETF Trust | 15,27% | 3.512 NS | 30 Aprile 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 14,19% | 2.414.193 SH | 08 Agosto 2026 | Giornaliero |
| GDOC · Goldman Sachs ETF Trust | 13,28% | 2.417 NS | 31 Maggio 2026 | N-PORT |
| RXL · ProShares Trust | 12,67% | 8.263 NS | 31 Maggio 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 12,13% | 370.443 NS | 30 Aprile 2026 | N-PORT |
| HRTS · Tema ETF Trust | 11,52% | 5.413 NS | 31 Maggio 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 10,68% | 15.801 NS | 30 Aprile 2026 | N-PORT |
| IXJ · iShares Trust | 10,58% | 369.006 SH | 08 Agosto 2026 | Giornaliero |
| SNPG · DBX ETF Trust | 7,01% | 852 NS | 29 Maggio 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 6,81% | 811 NS | 30 Aprile 2026 | N-PORT |
| LRND · New York Life Investments ETF Trust | 5,19% | 15.945 NS | 30 Aprile 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 5,03% | 21.491 SH | 08 Agosto 2026 | Giornaliero |
| JGRW · Trust for Professional Managers | 4,90% | 4.253 NS | 31 Maggio 2026 | N-PORT |
| CANC · Tema ETF Trust | 4,82% | 7.684 NS | 31 Maggio 2026 | N-PORT |
| SXQG · EXCHANGE TRADED CONCEPTS TRUST | 4,78% | 2.923 NS | 31 Maggio 2026 | N-PORT |
| EGGS · Tidal Trust III | 4,43% | 2.254 NS | 31 Maggio 2026 | N-PORT |
| FLAG · Global X Funds | 4,25% | 75 NS | 30 Aprile 2026 | N-PORT |
| CARK · Advisors' Inner Circle Fund II | 4,24% | 14.041 NS | 30 Aprile 2026 | N-PORT |
| DUHP · Dimensional ETF Trust | 4,21% | 511.432 NS | 30 Aprile 2026 | N-PORT |
| PJFG · PGIM ETF Trust | 4,16% | 5.851 NS | 29 Maggio 2026 | N-PORT |
| VIG · VANGUARD SPECIALIZED FUNDS | 4,14% | 4.469.091 SH | 08 Agosto 2026 | Giornaliero |
| XT · iShares Trust | 4,09% | 134.371 SH | 08 Agosto 2026 | Giornaliero |
| AMOM · Exchange Listed Funds Trust | 4,05% | 1.321 NS | 30 Aprile 2026 | N-PORT |
| MBCC · Northern Lights Fund Trust IV | 4,01% | 6.688 NS | 31 Maggio 2026 | N-PORT |
| PFM · Invesco Exchange-Traded Fund Trust | 3,95% | 26.928 SH | 08 Agosto 2026 | Giornaliero |
| CGUS · Capital Group Core Equity ETF | 3,92% | 384.824 NS | 31 Maggio 2026 | N-PORT |
| SEMG · EA Series Trust | 3,87% | 2.506 NS | 30 Aprile 2026 | N-PORT |
| GFGF · EA Series Trust | 3,86% | 1.296 NS | 29 Maggio 2026 | N-PORT |
| BWTG · ETF Opportunities Trust | 3,84% | 716 NS | 31 Maggio 2026 | N-PORT |
| BKCG · BNY Mellon ETF Trust II | 3,79% | 4.808 NS | 30 Aprile 2026 | N-PORT |
| TOPT · iShares Trust | 3,76% | 21.397 SH | 08 Agosto 2026 | Giornaliero |
| QUAL · iShares Trust | 3,71% | 1.492.544 SH | 08 Agosto 2026 | Giornaliero |
| GARP · iShares Trust | 3,71% | 87.685 SH | 08 Agosto 2026 | Giornaliero |
| HFGO · Hartford Funds Exchange-Traded Trust | 3,66% | 7.105 NS | 30 Aprile 2026 | N-PORT |
| RILA · Spinnaker ETF Series | 3,61% | 1.620 NS | 30 Aprile 2026 | N-PORT |
| AGNG · Global X Funds | 3,58% | 2.652 NS | 31 Maggio 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 3,56% | 331 NS | 31 Maggio 2026 | N-PORT |
| EGGY · Tidal Trust III | 3,54% | 4.039 NS | 31 Maggio 2026 | N-PORT |
| CGCV · Capital Group Conservative Equity E… | 3,52% | 55.867 NS | 31 Maggio 2026 | N-PORT |
| GDIV · Harbor ETF Trust | 3,51% | 8.487 NS | 30 Aprile 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 3,45% | 8.953 NS | 31 Maggio 2026 | N-PORT |
| CAPE · DoubleLine ETF Trust | 3,44% | 9.741 NS | 31 Marzo 2026 | N-PORT |
| GGUS · Goldman Sachs ETF Trust | 3,43% | 14.301 NS | 31 Maggio 2026 | N-PORT |
| GROZ · Zacks Trust | 3,41% | 2.787 NS | 31 Maggio 2026 | N-PORT |
| MGK · VANGUARD WORLD FUND | 3,39% | 943.950 SH | 08 Agosto 2026 | Giornaliero |
| IWY · iShares Trust | 3,35% | 463.234 SH | 08 Agosto 2026 | Giornaliero |
| NEWZ · EA Series Trust | 3,33% | 675 NS | 30 Aprile 2026 | N-PORT |